

Gastroenterology

Volume 170 / Issue 3

March 2026


www.gastrojournal.org

TABLE OF
CONTENTS

Contents

ON THE COVER

Gastroenterology



Mutational Landscape of Colorectal Tumors From Individuals With Polyposis. See article by Sommer, et al, page 557 for additional information.

IN MEMORIAM

445 In Memoriam: Pelayo Jesus Correa, MD (1927–2025)

K. T. Wilson, M. Blanca Piazuelo, M. Constanza Camargo, J. G. Fox, and R. M. Peek Jr.

COMMENTARIES

447 Hepatitis B Vaccination: A Remarkable Success Story That Must Continue

A. S. Lok, J. W. Ward, M.-H. Chang, and C. Cohen

452 A Normal UCEIS Is Zero: A Score Divided by a Common Language

J. Blackwell, A. Grayston, S. Din, S. Honap, S. Travis, and C. A. Lamb

456 Can Colonoscopy Still Be Promoted as the Best Choice for Colorectal Cancer Screening?

U. Ladabaum, D. S. Weinberg, and A. Castells

MENTORING, EDUCATION, AND TRAINING CORNER

463 Advancing Medical Education: A Structured Approach to Faculty Development in Gastroenterology

D. Virant-Young, K. Carpenter, and L. Elliott

EDITORIALS

466 Understanding Polyposis Development: Progress and the Many Remaining Challenges

X. Llor

See Sommer AK et al on page 557.

Video

Related article in CGH

Hot Papers From New Investigators

CME quiz

Editorial accompanies this article

Additional online content available

Cover

Publisher: *Gastroenterology* (ISSN 0016-5085) is published monthly (semi-monthly in April) in two indexed volumes by Elsevier Inc., 1600 John F. Kennedy Boulevard, Suite 1600, Philadelphia, PA 1910, United States. Periodicals postage paid at New York, NY and additional mailing offices. POSTMASTER: Send address changes to Elsevier, Journal Returns, 450 Fame Avenue, Hanover, PA 17331, USA. 2026 US subscription rates: individual, \$848.00; student and resident, \$323.00. Outside of the U.S. and possessions: individual, \$1026.00; student and resident, \$596.00; surface delivery, no additional charge; air mail delivery, add \$78.00. Prices subject to change without notice.

- 468 Too High, Just Right, or Not Enough? Rethinking Alpha-Fetoprotein Thresholds for Hepatocellular Carcinoma Screening**
N. Mehta and N. D. Parikh
 See Kim NJ et al on page 606.
- 470 Is a Goldilocks Solution for Colorectal Cancer Screening Just a Fairy Tale? Overdiagnosis Versus Later Diagnosis of Premalignant Lesions**
J. A. Dominitz and D. J. Robertson
 See Castells A et al on page 627.

GASTRO CURBSIDE CONSULT

- 473 A Rare Case of Recurrent Abdominal Pain With Facial Edema**
M. Huang, Y. Lian, and C. Xie

ELECTRONIC GASTRO CURBSIDE CONSULT

For a full list, please see the table of contents online at www.gastrojournal.org.

REVIEWS IN BASIC AND CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

- 476 Epidemiology, Natural History, and Treatment of Eosinophilic Gastrointestinal Diseases**
P. Visaggi and E. S. Dellon

ORIGINAL RESEARCH

Full Reports

GI Cancer

- 495 Gastric Organoid-Based Ectopic and Orthotopic In Vivo CRISPR Screening for Tumor Suppressors in Gastric Cancer**
J. He, G. Papa, F. Azizi, L. Kirsche, M. Artola-Boran, R. Ferreira Cassio, A. L. Hotz, G. Geiger, B. Francas, A. Weber, A. Tzankov, Z. Kontarakis, P. Leary, and A. Müller

Transplantation of genetically modified organoids into the mouse stomach generates tumors that recapitulate the mutation spectrum and major risk factors, such as *Helicobacter pylori* infection, of human stomach cancer.

Inflammatory Bowel Disease

- 511 Postoperative Ileum Transcriptomics Implicate Sex-Biased Mechanisms in Crohn's Disease Recurrence**

K. Gettler, S. Nagpal, S. Washburn, C. Tastad, J. Zhang, K. Sabic, M. Lazarev, A. Bitton, R. Cohen, M. B. Schwartz, A. Barrie, P. Gu, P. Fleshner, M. Bao, C. Hernández-Rocha, J. McCauley, M. Abreu, S. Kugathasan, D. P. McGovern, S. R. Brant, R. H. Duerr, M. S. Silverberg, J. D. Rioux, G. Gibson, and J. H. Cho

Male patients with Crohn's disease were found to have more pronounced differences in expression than female patients when comparing recurrent and nonrecurrent samples.

- 523 Fecal Detection of Calprotectin Subunits Links Inflammatory Bowel Disease Activity With Chronicity of Intestinal Inflammation**

A. Jukic, R. Hilbe, L. Zundel, P. Willeit, K. Faserl, C. Plattner, A. Zollner, M. Meyer, K. Siegmund, V. Klepsch, V. Marteau, A. Vich Vila, J. Schwärzler, K. Vouk, A. Kozsar, D. Rieder, A. Weichberger, B. Sarg, F. Grabherr, L. Mayr, P. Moser, N. Nemati, S. Scholl-Bürgi, D. Karall, G. F. Vogel, L. Welz, D. Aldrian, R. Koch, A. Pfister, Q. Ran, A. Kaser, R. S. Blumberg, I. Tancevski, F. Sommer, P. Bacher, S. Schreiber, P. Rosenstiel, K. Aden, G. Baier, L. Bakiri, T. Müller, G. Weiss, TRR241 IBDome Consortium, R. K. Weersma, Z. Trajanoski, E. F. Wagner, H. Tilg, and T. E. Adolph

This study resolves enterol calprotectin protein configurations and related inflammatory actions in inflammatory bowel diseases, paving the way for novel biomarker-guided therapies in inflammatory bowel diseases.

539 The Gut Microbiome at the Onset of Inflammatory Bowel Disease: A Systematic Review and Unified Bioinformatic Synthesis

Peter Rimmer, F. Zhang, G. Scott, Microbiome Data Provision Group, G. L. Hold, M. Gordon, T. H. Iqbal, and R. Hansen

Gut bacteria are important in causing inflammatory bowel diseases. By combining the results from published studies, the authors have identified key changes in these bacteria that might help develop new diagnostic and treatment approaches.

Colon

557 Mutational Landscape of Colorectal Tumors From Individuals With Unexplained Adenomatous or Serrated Colorectal Polyposis

A. K. Sommer, I. B. A. W. te Paske, E. A. M. Jansen, A. Gschwind, G. Demidov, V. Steinke-Lange, I. Spier, W. Steyaert, B. Yaldiz, M. Steehouwer, O. Hommerding, D. Dietrich, S. Peters, J. Garcia-Pelaez, A. Laner, C. Oliveira, G. Capellá, I. D. Nagtegaal, H. Bläker, K. Ellwanger, A. Hoischen, C. Gilissen, R. S. van der Post, G. Kristiansen, N. Hoogerbrugge, S. Ossowski, L. Valle, E. Holinski-Feder, M. J. L. Ligtenberg, S. Aretz, and R. M. de Voer

See editorial on page 466.

Comprehensive molecular profiling was done of an extensive series of (pre)malignant lesions from individuals with genetically unexplained polyposis and/or early-onset colorectal cancer to better understand the early steps of tumor development.

Hepatobiliary

569 Clusterin Drives Fiber Endocytosis by Mesothelial Cells to Resolve Liver Fibrosis

M. Wang, F. Chen, J. Gao, Q. Liu, Z. Li, Q. Kong, Y. Liu, Y. Pang, Z. Wang, Y. Zhou, L. Zhang, K. Jia, S. Lu, S. Liu, J. Yuan, X. He, H. Liu, X. Li, and J. Hou

The pericentral senescent hepatocytes secrete clusterin to activate the endocytosis of fibers by hepatic mesothelial cells and resolve liver fibrosis, which is mimicked by the engineered CLUtide for the therapy.

Endoscopy

584 Endoscopic Ultrasound-Guided Choledochoduodenostomy vs Endoscopic Retrograde Cholangiopancreatography in Malignant Distal Biliary Obstruction to Prevent Postprocedural Pancreatitis: A Randomized Trial

A. Anderloni, M. Spadaccini, C. Binda, A. Mauro, S. Stigliano, L. Carrozza, M. Colombo, S. Mazza, C. Coluccio, A. Amato, M. Andreozzi, G. E. Maria Rizzo, A. Facciorusso, F. Radaelli, S. Carrara, B. Mangiavillano, F. M. Di Matteo, I. Tarantino, C. Hassan, A. Repici, A. Fugazza, and C. Fabbri

This randomized trial showed endoscopic ultrasound-guided choledochoduodenostomy significantly reduces postprocedural pancreatitis risk compared with endoscopic retrograde cholangiopancreatography, with better technical efficiency and similar clinical efficacy, supporting its use as a primary option in selected patients with dilated common bile duct.

Prevention and Early Detection

595 Utility of Serum Biomarkers in Addition to Ultrasound for Early Detection of Hepatocellular Carcinoma in High-Risk Patients: A Randomized Controlled Trial

G. Hirode, H. F. Zangneh, O. Cerochi, K. Khalili, L. A. El-Karim, C. Kandel, M. Vecchio, J. Winick, Y. Mori, H. Yamada, H. L. A. Janssen, B. E. Hansen, M. Sherman, and J. J. Feld

The addition of the biomarkers α -fetoprotein, lectin-reactive fraction of α -fetoprotein, and des-gamma-carboxy prothrombin to biannual ultrasound surveillance did not enhance the detection of liver cancer at a curable stage. Establishing optimal thresholds and identifying specific patient populations is crucial for early-stage liver cancer detection using biomarkers.

606 Changes in Liver Disease Etiology Support a Lower Alpha-Fetoprotein Threshold for Hepatocellular Carcinoma Screening

N. J. Kim, M. Li, P. Vutien, B. Mecham, J. Borgerding, K. Swarts, P. Atuluru, M. C. Michel, A. Barnard Giustini, C. Mezzacappa, K. Berry, T. VoPham, T. L. Marsh, Z. Feng, K. M. Johnson, L. A. Beste, D. E. Kaplan, T. H. Taddei, and G. N. Ioannou

See editorial on page 468.

In this study, we estimated the serum alpha-fetoprotein test's performance for liver cancer screening in patients with cirrhosis. We found that lowering the threshold from ≥ 20 to ≥ 10 ng/mL can promote better detection of liver cancer.

RESEARCH LETTERS

- 619 HLA Heterozygosity Influences Colorectal Cancer Risk and Survival Outcome**
 Y.-Y. Tsai, C. E. Thomas, P. J. Law, Z. Chen, S. B. Gruber, S. L. Schmit, and International Colorectal Cancer GWAS Collaborative
- 623 MLH1 Lynch Syndrome Colorectal Cancers Are Driven by Heterogeneous Wnt Pathway Gene Mutations**
 K. E. Hokkanen, J. Panula, J. Böhm, J.-P. Mecklin, P. Peltomäki, T. T. Seppälä, and Lynch Syndrome MLH1 CRC Group
- 627 Characteristics of Colonoscopy- and Fecal Immunochemical Test-Based Screen-Detected Premalignant Neoplastic Lesions: Results From the COLONPREV Study**
 A. Castells, E. Quintero, M. Pellisé, E. Frías-Arrocha, C. Hernández, and M. Serra-Burriel, On behalf of the COLONPREV Study Investigators
 See editorial on page 470.
- 631 Progression of Pancreatic Morphologic Changes and Endocrine Dysfunction After Acute Pancreatitis: Preliminary Results of the Longitudinal Goulash-Plus Cohort Study**
 A. Mikó, N. Farkas, Á. Vincze, F. Izbéki, A. Szentesi, P. Hegyi, and Hungarian Pancreatic Study Group

CONTINUING MEDICAL EDUCATION (CME)/MOC ACTIVITIES

- e5 CME Exam 1: Postoperative Ileum Transcriptomics Implicate Sex-Biased Mechanisms in Crohn's Disease Recurrence**

GASTRO DIGEST

- 635 Microscopic Colitis: Clearing the Usual Suspects**
 D. Keszthelyi
- 635 Global Incidence and Prevalence of Inflammatory Bowel Disease Over Time**
 R. Khanna and M. E. Kuenzig
- 636 Learning to Tolerate: Searching for the Cells Responsible for Food Antigen Tolerance**
 A. B. Muir
- 637 Turning Gut Sensors Into Therapeutic Switches: A Sensorome Roadmap for Metabolic and Gut-Brain Interaction Disorders**
 R. Singh and K. G. Margolis

CORRESPONDENCE

- 639 From Identification to Intervention: Advancing Ethical Governance for AI Bias in Gastroenterology**
 M. Li and M. Xu
- 639 Essentiality of Liver Failure in Acute or Chronic Liver Failure and Its Implications**
 A. K. Mishra
- 640 Gene-Specific Adenoma Detection in Lynch Syndrome: Methodological Considerations and Clinical Implications**
 L. Zhou and A. Sun

- 641 Reply**
A. Sánchez, J. Castillo-Iturra, and F. Balaguer
- 642 The Prospects of MEK Inhibitors in the Treatment of Gastric Precancerous Lesions**
P. Zheng, X. Xu, Y. Wei, and C. Lei
- 643 Reply**
J. R. Goldenring, E. Choi, and S. Nomura
- 644 Global MASLD Consensus: Inclusive in Scope, Exclusive in Therapy?**
A. Kumar
- 645 Re-evaluating Lifestyle Interventions in Normal Weight Metabolic Dysfunction-Associated Steatotic Liver Disease**
A. S. Bhadoria and S. Sinha
- 646 Reply**
L. Henry, S. Zelber-Sagi, and Z. M. Younossi
- 647 Concerns Regarding Endoscopic Band Ligation for Dieulafoy Lesions**
K. B. Lankarani
- 648 Reply**
F. Tse, A. N. Barkun, L. Laine, and G. I. Leontiadis
- 648 A Response to “Heavy Metals and Inflammatory Bowel Disease” Using Linked Sources of Real-World Data**
M.-Y. Chen, G. Onal, A. Mukherjee, A. Ayati, and V. A. Rudrapatna
- 649 Reply**
S. Narvey, J.-E. Ghia, and C. N. Bernstein
- 650 Clock-Constrained Evacuation and Model Over-Reach: Comment on Lamichhane et al**
K. Huang
- 651 Reply**
R. Lamichhane, J. Chen, and A. E. Bharucha
- 652 Comments on the Role of TL1A/DR3 Signaling and Th9 Cells in Crohn’s Disease**
L. Pan and G. Wang
- 653 Reply**
P. Menghini, G. Bamias, and F. Cominelli
- 654 Cautious Implementation of *Helicobacter pylori* Eradication in the Elderly**
C. Yang, Z. Shi, and C. Zhang